anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hypertension is an established risk factor for mild cognitive impairment (MCI) in elderly individuals. Nevertheless, the impact of different levels of blood pressure on the progression of MCI remains uncertain. This study aims to investigate the non-linear relationship between blood pressure and MCI in the elderly and detect the critical blood pressure threshold, thus, improving blood pressure management for individuals at high risk of MCI.
METHODS: Data was obtained from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) cohort. We chose normal cognitive elderly individuals who entered the cohort in 2014 for a 5-year follow-up to observe the progression of MCI. Subsequently, we utilized the Cox regression model to identify risk factors for MCI and conducted a Cox-based restricted cubic spline regression (RCS) model to examine the non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) with MCI, determining the critical blood pressure threshold for MCI progression.
RESULTS: In the elderly population, female (HR = 1.489, 95% CI: 1.017-2.180), lacking of exercise in the past (HR = 1.714, 95% CI: 1.108-2.653), preferring animal fats (HR = 2.340, 95% CI: 1.348-4.061), increased age (HR = 1.061, 95% CI: 1.038-1.084), increased SBP (HR = 1.036, 95% CI: 1.024-1.048), and increased DBP (HR = 1.056, 95% CI: 1.031-1.081) were associated with MCI progression. After adjusting factors such as gender, exercise, preferred types of fats, and age, both SBP (P non-linear < 0.001) and DBP (P non-linear < 0.001) in elderly individuals exhibited a non-linear association with MCI. The risk of MCI rose when SBP exceeded 135 mmHg and DBP was in the range of 80-88 mmHg. However, when DBP exceeded 88 mmHg, there was a declining trend in MCI progression, although the HR remained above 1. The identified critical blood pressure management threshold for MCI was 135/80 mmHg.
CONCLUSION: In this study, we discovered that risk factors affecting the progression of MCI in elderly individuals comprise gender (female), preferring to use animal fat, lack of exercise in the past, increased age, increased SBP, and increased DBP. Additionally, a non-linear relationship between blood pressure levels and MCI progression was confirmed, with the critical blood pressure management threshold for MCI onset falling within the prehypertensive range.
The invention discloses a preparation method of honey medicinal liquor, and relates to the field of medicinal liquor. The honey medicinal liquor is prepared from 50-100 parts of honey, 200-300 parts of spring water, 100-800 parts of white spirits, 30-40 parts of radix angelica sinensis, 3-6 parts of fructus lycii, 2-6 parts of ginseng, 10-15 parts of radix glycyrrhizae and 0-2 parts of fruit flavor additive. The preparation method includes the steps of firstly, diluting honey with spring water to form honeydew; secondly, heating honeydew, keeping the temperature and then cooling honeydew; thirdly, putting radix angelica sinensis, fructus lycii, ginseng and radix glycyrrhizae in a bottle, filling the bottle with spring water to conduct soaking, and obtaining liquid medicine; fourthly, mixing honeydew with liquid medicine, adding an appropriate amount of fruit flavor additive, and obtaining mixed liquid; fifthly, pouring mixed liquid into white spirits, conducting fermentation three times, and obtaining honey medicinal liquor. The honey medicinal liquor can be easily absorbed by human bodies. Various types of amino acid of ginseng and fructus lycii can be separated out, and the effects of treating and preventing cardiovascular and cerebrovascular diseases are achieved. People can not feel headaches even when drinking the liquor a little bit more, and due to the fact that amino acid is contained in honey, people can have a decent sleep and get up with refreshed feelings after drinking the liquor.
Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
BACKGROUND: The gastric conduit is the most commonly used replacement organ for reconstruction after minimally invasive McKeown esophagectomy. Although the optimal route of gastric conduit remains controversial, the posterior mediastinal route is physiologically preferable but is not without disadvantages. Here, we report the safety and efficacy of a method of gastric conduit reconstruction via the anterior of the pulmonary hilum route.
METHODS: We have used the anterior of the pulmonary hilum route since 2021. This procedure involves pulling the gastric conduit up through a substernal tunnel between the right thoracic cavity and the abdominal cavity and passing it into the neck via the anterior of the pulmonary hilum route. In this retrospective study, we compared the clinical outcomes between 20 patients who underwent this procedure and 20 patients who underwent the posterior mediastinal route from 2021 to 2022.
RESULTS: No mortality was reported in either group. No significant differences were observed between the two groups in duration of surgery, blood loss, incidence of postoperative complications, and postoperative hospital stay. As a result of the anterior of the pulmonary hilum route, the primary tumor bed and lymph node drainage area were effectively bypassed, which facilitates postoperative adjuvant radiotherapy or chemoradiotherapy. The distance of the gastric conduit accompanying the airway was significantly shorter in the anterior of the pulmonary hilum route group.
CONCLUSIONS: Our method is considered to be a safe and useful technique for the reconstruction of gastric conduit.
Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
Participants and Methods: A randomize controlled trial will be conducted by comparing the change in the skin surface temperature before and after using acupunture at the control acupoint (Yuji - LU10) and the research acupoint (Houxi - SI3) on either the left or right hand in healthy volunteers. A total of 60 participants will be randomly assigned to 2 group (A and B) and the allocation was 1:1. Both groups will undergo two trial phases 07 days apart, corresponding to one acupoint on the same hand in each step. Group A (acupoints on the left hand): participants will be received acupuncture at the control acupoint (Yuji - LU10) in the first trial phase, and the second phase will be conducted after 07 days at the research acupoint (Houxi - SI3). Group B: proceeding similarly to group A, but the points are on the right hand. The primary outcome will be the change in skin surface temperature at the neck when using acupuncture at Houxi point on each hand. This trial will be performed as a 2-arm parallel design, randomize, controlled and single blinded.
PROBLEM TO BE SOLVED: To obtain the subject composition, containing a laccase, formable into a foamy shape at the time of use, hardly causing damage to hair and capable of effectively dyeing hair of the head. SOLUTION: This composition for hair dyeing contains preferably 0.005-0.5 wt.% laccase, preferably a developing substance (e.g. paraphenylenediamine, paraaminophenol or toluene-2, 5-diamine) and 0.1-5 wt.% coupler ingredient, 0.1-2.0 wt.% surfactant (e.g. a polyoxyethylene stearyl ether, a polyoxyethylene hardened castor oil, a coconut oil fatty acid diethanolamide or stearylmethylammonium chloride), 0.05-5.0 wt.% water-soluble polymer (e.g. a cationic cellulose or hydroxyethyl cellulose) and is formed into a foamy shape at the time of use. Furthermore, an oil, a humectant, a lower alcohol, a thickener, an antioxidant, a chelating agent, an agent for imparting the feeling of use or the like can be formulated in the composition.
Pregnancy Category C. There are no adequate and well-controlled studies of zanamivir in pregnant women. Zanamivir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Embryo/fetal development studies were conducted in rats (dosed from days 6 to 15 of pregnancy) and rabbits (dosed from days 7 to 19 of pregnancy) using the same IV doses (1, 9, and 90 mg/kg/day). Pre- and post-natal developmental studies were performed in rats (dosed from day 16 of pregnancy until litter day 21 to 23). No malformations, maternal toxicity, or embryotoxicity were observed in pregnant rats or rabbits and their fetuses. Because of insufficient blood sampling timepoints in rat and rabbit reproductive toxicity studies, AUC values were not available. In a subchronic study in rats at the 90 mg/kg/day IV dose, the AUC values were greater than 300 times the human exposure at the proposed clinical dose.

An additional embryo/fetal study, in a different strain of rat, was conducted using subcutaneous administration of zanamivir, 3 times daily, at doses of 1, 9, or 80 mg/kg during days 7 to 17 of pregnancy. There was an increase in the incidence rates of a variety of minor skeleton alterations and variants in the exposed offspring in this study. Based on AUC measurements, the 80 mg/kg dose produced an exposure greater than 1,000 times the human exposure at the proposed clinical dose. However, in most instances, the individual incidence rate of each skeletal alteration or variant remained within the background rates of the historical occurrence in the strain studied.

Zanamivir has been shown to cross the placenta in rats and rabbits. In these animals, fetal blood concentrations of zanamivir were significantly lower than zanamivir concentrations in the maternal blood.
In this study we will analyze Google queries of patients hospitalized in the Tel-Aviv Sourasky Medical Center with stroke, between the years 2016-2020. following the formal completion of the signed informed consent form, consenting subjects will personally request their search data from Google Takeout service from up to 2 years before to one year after the stroke and provide access to the researchers by creating a one-time file of these data and sharing them with the researchers. Following an informed consent data of Google queries will extracted by the participants using google "Take Out" service, from up to 2 years before to one year after the stroke. The control groups will consist of patients diagnosed with acute myocardial infarction (MI) and MI/stroke -free patients' spouses. Recruitment will be primarily from two institutionally approved data bases of stroke and acute MI. A total of 450 participants will be recruited, 150 in each group, based on prior experience for the minimally-sized dataset of query logs needed to construct a model and test its performance.

Anonymity will be guaranteed through several modalities; access to the Google Takeout data will be limited to the minimal amount required to perform the research and will be given only to members of the data analysis team in the Tel-Aviv University, while access to the medical data will be provided only to researchers from the Tel-Aviv Sourasky Medical Center. Additionally, members of the Tel-Aviv University Partner Team will be obligated to refrain from any positive attempts to identify subjects participating in the trial. All data shared with Tel-Aviv University will be stored on a local, encrypted, hard disk. The data will be deleted from Tel-Aviv University's computers at the end of the project.

Our previously developed Machine Learning model, which was able to predict stroke in subjects as compared to age matched controls with an area under curve (AUC) of 0.972 which translates to a positive predictive value of 52.7% at a false-positive rate of 1%, will be used to predict, for each day, the likelihood that a person will undergo a stroke event on that day. This will be compared to the known date of stroke or MI. The measure of performance will be the Receiver Operating Curve (ROC) of the detection and the corresponding Area Under Curve (AUC). Additionally, a new model will be trained using the collected data and tested similarly, albeit using 10-fold cross-validation. Stroke detection sensitivity and specificity will be derived.
BACKGROUND: Approximately 40 to 60% of patients with sepsis develop sepsis-induced cardiomyopathy (SIC), which is associated with a substantial increase in mortality. We have found that molecular hydrogen (H2) inhalation improved the survival rate and cardiac injury in septic mice. However, the mechanism remains unclear. This study aimed to explore the regulatory mechanism by which hydrogen modulates autophagy and its role in hydrogen protection of SIC.
METHODS: Cecal ligation and puncture (CLP) was used to induce sepsis in adult C57BL/6J male mice. The mice were randomly divided into 4 groups: Sham, Sham + 2% hydrogen inhalation (H2), CLP, and CLP + H2 group. The 7-day survival rate was recorded. Myocardial pathological scores were calculated. Myocardial troponin I (cTnI) levels in serum were detected, and the levels of autophagy- and mitophagy-related proteins in myocardial tissue were measured. Another four groups of mice were also studied: CLP, CLP + Bafilomycin A1 (BafA1), CLP + H2, and CLP + H2 + BafA1 group. Mice in the BafA1 group received an intraperitoneal injection of the autophagy inhibitor BafA1 1 mg/kg 1 h after operation. The detection indicators remained the same as before.
RESULTS: The survival rate of septic mice treated with H2 was significantly improved, myocardial tissue inflammation was improved, serum cTnI level was decreased, autophagy flux was increased, and mitophagy protein content was decreased (P < 0.05). Compared to the CLP + H2 group, the CLP + H2 + BafA1 group showed a decrease in autophagy level and 7-day survival rate, an increase in myocardial tissue injury and cTnI level, which reversed the protective effect of hydrogen (P < 0.05).
CONCLUSION: Hydrogen exerts protective effect against SIC, which may be achieved through the promotion of autophagy and mitophagy.
Peptides are provided that comprise an N-formyl methionine in which the methyl group of the side chain of methionine has been substituted with one or more halogens such as fluorine. The N-formyl. halogen-substituted methionine exhibits resistance to oxidation. Peptides comprising the N-formyl. halogen- substituted methionine may be utilized as agonists for formyl peptide receptor-1 (FPR-1) and may be conjugated to antibodies or antigen-binding fragments thereof. The antibody conjugates thusly prepared may be utilized to target cells and attract and activate immune cells that comprise the FPR-1 against the targeted cells.
Clinical experience with INVEGA® in patients with certain concomitant illnesses is limited [see Clinical Pharmacology (12.3)].

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

INVEGA® has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were excluded from premarketing clinical trials. Because of the risk of orthostatic hypotension with INVEGA®, caution should be observed in patients with known cardiovascular disease [see Warnings and Precautions (5.9)].
Parents of children less than 11 months of age will be identified as delayed or missing vaccinations due to logistic barriers in the Kaiser Permanente Colorado population. Parents identified will be randomized to the intervention arm or the usual care arm. Those in the intervention arm will receive automated reminders for the 6 month and 12 month vaccine visits. Reminders will include scheduling information as well as access to a website with vaccine and scheduling information. They will also have an opportunity to provide preferences in how they receive the automated reminders (text, phone or email). There will be 2 reminders before the 6 and 12 month visits and 2 after the 6 and 12 month visits. Parents will be excluded from receiving reminders if they have received vaccines within the time frame when they are eligible to receive another vaccine or have a well child visit scheduled.
A Circuit Training Combine with Square-Stepping Exercise, Strength training and balance training. The intervention time and frequency of this study were 12 weeks, 2 times a week, 24 times in total, 1.5 hours each time (30 minutes of main exercise).
PURPOSE:To promote the formation of a new bone by filing a bone depleted or gap part and to improve bio-compatibility capable of unifying bone tissue, by granulating a mixture obtained by mixing a hydroxyapatite have a specific average particle size and crystalline cellulose in a specific ratio into granules having a specific particle size and subsequently baking said granules. CONSTITUTION:Hydroxyapatite is ground as fine as possible to obtain a hydroxyapatite powder having an average particle size of 0.1-10mum, pref., 0.5-7mum. Crystalline cellulose is compounded in order to form closed cells having a desired pore size when hydroxyapatite is sintered and has continuous cells having a pore size of 10-100mum and, in order to obtain a porous granules having a void ratio of 20-50%, one having an average particle size of 10-100mum, is compounded in a ratio of 25-100pts.wt. of 100pts. of the hydroxyapatite powder. This mixture is granulated into granules having a particle size of 0.1-3.0mm and the obtained granules are gradually heated to 900-1,400 deg.C and baked at this temp. The granular porous hydroxyapatite sintered body thus obtained is formed into a uniform slurry before use by adding a physiological saline solution to said sintered body.
Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Neuronal pentraxin 2 (Nptx2), a member of the synaptic protein family linked to excitatory synaptic formation, is found to be upregulated in epileptic mice, yet its role in epilepsy has been unclear. In vivo, we constructed a mouse model of epilepsy by using kainic acid induction. In vitro experiments, a Mg2+-free medium was used to induce epileptiform discharges in neurons. The results showed that the Nptx2 was upregulated in epileptic mice. Moreover, Nptx2 knockdown reduced the number of seizures and seizure duration. Knocking down Nptx2 not only reduced the number and duration of seizures but also showed a decrease in electroencephalogram amplitude. Behavioral tests indicated improvements in learning and memory abilities after Nptx2 knockdown. The Nissl staining and Timms staining revealed that Nptx2 silencing mitigated epilepsy-induced brain damage. The immunofluorescence staining revealed that Nptx2 absence resulted in a reduction of apoptosis. Nptx2 knockdown reduced Bax, cleaved caspase3, and cleaved caspase9 expression, while increased Bcl-2 expression. Notably, Nptx2 knockdown inhibited GluA1 phosphorylation at the S831 site and reduced the GluA1 membrane expression. The PSD95 expression declined in the epilepsy model, while the Nptx2 knockdown reversed it. Collectively, our study indicated that Nptx2 silencing not only alleviated brain damage and neuron apoptosis but also improved learning and memory ability in epileptic mice, suggesting Nptx2 as a promising target for epilepsy treatment.
PURPOSE: The experience of long-term pain in head and neck cancer (HNC) survivors is important but has received less attention in the HNC literature. The present study sought to examine the prevalence of pain from 2 to 5 years postdiagnosis and its association with HNC-specific health-related quality of life.
MATERIALS & METHODS: Prospective observational study at a single-institution tertiary care center. Pain was measured using a single item ranging from 0 to 10 with 0 representing no pain and 10 representing worst pain possible at 2 through 5 years postdiagnosis. HNC-specific HRQOL was measured using the Head and Neck Cancer Inventory (HNCI).
RESULTS: Pain reports were consistent across time. At 2 years postdiagnosis (N = 581), 27.6 % experienced at least some pain with 14.3 % reporting moderate or severe pain. At 3 years postdiagnosis (N = 417), 21.4 % experienced at least some pain with 14.2 % indicating moderate or severe pain. At 4 years postdiagnosis (N = 334), 26.7 % experienced at least some pain with 15.9 % reporting moderate or severe pain. At 5 years postdiagnosis (N = 399), 30.5 % experienced at least some pain with 17.5 % indicating moderate or severe pain. In general, across all four HNCI domains, those in the moderate and severe pain categories largely failed to reach 70 which is indicative of high functioning on the HNCI.
CONCLUSIONS: Pain is a considerable issue in long-term HNC survivors up to 5 years postdiagnosis. More research is needed to understand correlates of pain after treatment, including opportunities for screening and intervention, to improve outcomes and optimize recovery in HNC.
Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
161,341. Thomson, D. Jan. 23, 1920. Vaccines.-Non-toxic vaccines are prepared from germs by separating the alkali-, acid-, and alcohol-soluble portions by successive precipitations. Tubercle bacilli, gonococci, or Pfeiffer bacilli are treated with an alkaline solution and the solid residue removed. The solution is treated with acid, and the resulting precipitate is neutralized and then treated with alcohol to form a precipitate A. The acid solution is treated with alcohol to yield a precipitate B. The residue of the germ substance not soluble in alkali is treated with acid, and the solution obtained is rendered alkaline to give a precipitate C, and then treated with alcohol to give a precipitate D. The residue of germ substance not dissolved by the alkali or bv the acid is treated with alcohol to give a solution from which a precipitate E is obtained by the addition of salt solution, and the final residue of germ substance is treated with chloroform to obtain an extract which is evaporated to dryness and washed with alcohol to yield a residue F. The substances A, C, E, and F, with or without Band D, are emulsified with normal saline solution and standardized for use as vaccines. Specification 136,036 is referred to.